Paper II — 2024 March (Supplementary) (2019 Scheme) — Q12

Paper II

2024 March (Supplementary) (2019 Scheme) · 100 marks · 180 min

Question

Diagnostic IHC makers of any four tumors

Q124 marksShort Answers★✓

Answer

Diagnostic immunohistochemical (IHC) markers of four representative tumours:

1. Breast carcinoma: ER (Estrogen Receptor), PR (Progesterone Receptor), and HER2/neu — used for diagnosis, prognosis, and to guide hormonal/targeted therapy; GATA3 as a lineage marker.
2. Prostatic adenocarcinoma: PSA (Prostate-Specific Antigen) and PSAP (Prostatic Specific Acid Phosphatase); basal cell markers (p63, high molecular weight cytokeratin/CK5/6) are absent in malignant glands, helping distinguish carcinoma from benign glands (which retain a basal cell layer).
3. Hodgkin lymphoma (classic type): CD15 and CD30 positive on Reed-Sternberg cells (CD45/CD20 typically negative).
4. Ewing sarcoma/PNET: CD99 (MIC2) — strong, diffuse membranous positivity.

(Other well-known examples: Melanoma — S100, HMB-45, Melan-A; Neuroendocrine tumours — Chromogranin, Synaptophysin; GIST — CD117/c-KIT, DOG1.)

Related Concepts

1. 1Hodgkin Lymphoma

Other Years Asked

1. 1Classify Hodgkin Lymphoma. Describe the morphological features and immunohistochemical profile of Classical Hodgkin Lymphoma2022 July (Supplementary) (2019 Scheme)Short Essay · 8 marks
2. 2Hodgkin’s lymphoma2024 March (Supplementary) (2019 Scheme)Short Essay · 8 marks
3. 3Hodgkin’s lymphoma2024 June (Supplementary) (2019 Scheme)Short Essay · 8 marks
4. 4Hodgkin’s lymphoma2025 March (Supplementary (SAY)) (2019 Scheme)Short Essay · 6 marks
5. 5Classical Hodgkin lymphoma subtypes are2024 December (Supplementary) (2019 Scheme)MCQ · 1 mark
6. 6Multinucleate giant cells are seen in2025 March (Supplementary (SAY)) (2019 Scheme)MCQ (Multi) · 1 mark